英国常规临床实践中老年原发性中枢神经系统淋巴瘤患者的结局:甲氨蝶呤剂量强度与缓解和生存相关
该回顾性研究纳入英国14个中心2012—2017年诊断的≥65岁原发性中枢神经系统淋巴瘤患者244例,其中192例接受以甲氨蝶呤为基础的治疗。按临床医生选择分为姑息组52例、低强度组74例和高强度组118例,高强度组完全缓解率、2年无进展生存率和总生存率均高于低强度组。较高的甲氨蝶呤相对剂量强度与无进展生存和总生存改善相关。
要点
- 低强度组完全缓解率49%、2年无进展生存率11%、2年总生存率24%,高强度组分别为69%、40%、50%。
- 接受甲氨蝶呤治疗的患者治疗相关死亡率为6.8%。
- 甲氨蝶呤中位累积剂量为8.8 g/m²(范围1.5-21),中位3个周期。
核心结论
- 这些回顾性数据提示,最大化甲氨蝶呤相对剂量强度并在部分老年患者中给予巩固治疗可能改善临床结局。
- 完成以甲氨蝶呤为基础诱导和巩固治疗的老年患者临床结局与年轻队列相似。
研究设计与样本
- 回顾性审查英国14个中心2012—2017年诊断的连续≥65岁原发性中枢神经系统淋巴瘤患者244例的医疗记录。
- 其中192例接受以甲氨蝶呤为基础的治疗。
- 按临床医生治疗选择分为姑息组52例、低强度组74例(甲氨蝶呤±利妥昔单抗±烷化剂)和高强度组118例(甲氨蝶呤/阿糖胞苷联合方案)。
主要发现
- 低强度组完全缓解率49%、2年无进展生存率11%、2年总生存率24%;高强度组分别为69%、40%、50%。
- 接受甲氨蝶呤治疗的患者治疗相关死亡率为6.8%。
- 甲氨蝶呤中位累积剂量为8.8 g/m²(范围1.5-21),中位3个周期。
- 调整年龄、东部肿瘤协作组(ECOG)评分和基线参数后,较高的甲氨蝶呤相对剂量强度与两组无进展生存和总生存改善均相关。
- 接受4个或以上诱导周期后巩固治疗的患者(n=36)2年无进展生存率和总生存率分别为65%和70%。
关键数值与推荐
- 低强度组完全缓解率49%、2年无进展生存率11%、2年总生存率24%;高强度组分别为69%、40%、50%。
- 接受甲氨蝶呤治疗的患者治疗相关死亡率为6.8%。
- 甲氨蝶呤中位累积剂量为8.8 g/m²(范围1.5-21),中位3个周期。
- 接受4个或以上诱导周期后巩固治疗的患者(n=36)2年无进展生存率和总生存率分别为65%和70%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Data on older patients with primary central nervous system lymphoma (PCNSL) are scarce. Comorbidities and performance status frequently compromise outcomes in this group. Medical records for consecutive patients ≥65 years (n = 244) with PCNSL diagnosed 2012-2017 from 14 UK centres were retrospectively reviewed. Of these 192 patients received methotrexate (MTX)-based treatment. Patients were categorised based on clinician's treatment choice into 'palliative' (n = 52), 'less intensive: MTX ± rituximab ± alkylators' (n = 74) and 'intensive: MTX/cytarabine combinations' (n = 118) groups. Complete remission (CR) rate, two-year progression-free survival (PFS) and overall survival (OS) rates were 49%, 11% and 24% for the less intensive and 69%, 40% and 50% for the intensive groups. Treatment-related mortality (TRM) was 6·8% for MTX-treated patients. Median MTX cumulative dose was 8·8 g/m2 (range 1·5-21) over a median of three cycles. Higher relative dose intensity of MTX (MTX-RDI) was associated with improved PFS and OS in both groups adjusting for age, Eastern cooperative oncology group (ECOG) score and baseline parameters. Two-year PFS and OS for patients receiving four or more induction cycles followed by consolidation (n = 36) were 65% and 70% respectively. Older patients completing MTX-based induction and consolidation had clinical outcomes similar to those in younger cohorts. These retrospective data suggest that maximising MTX-RDI and delivering consolidation in a subgroup of older patients may improve clinical outcomes.
引用
- Martinez-Calle N, Poynton E, Alchawaf A, et al. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival. Br J Haematol. 2020. PMID: 32232989. doi:10.1111/bjh.16592
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。